The modest efficacy and toxic effects of Bayer AG/Onyx Pharmaceuticals Inc.’s Stivarga (regorafenib) suggest the drug is unlikely to be cost-effective in advanced colon cancer, according to an editorial in the Lancet, in what is becoming a familiar refrain in the crowded, expensive treatment space.
The Nov. 22 editorial, written by U.K. oncologists, comes as the drug is under review in Europe for metastatic colorectal...